Ori segal - research

F2F examination was predefined as the reference standard.

Of these, 217 eyes (50.94%) had neovascular age-related macular degeneration (NVAMD), 151 (35.45%) diabetic macular edema (DME), and 56 (13.15%) retinal vein occlusion (RVO; 36 branch RVO, 14 central RVO, and 6 hemi-retinal RVO).

One eye (0.23%) had myopic choroidal neovascularization (CNV), and one (0.23%) had Sorsby macular dystrophy with CNV.

The mean virtual review time was more than twofold shorter than the F2F evaluation ( P < 0.001).

Patients had previously received intravitreal injections of medications including bevacizumab, ranibizumab, aflibercept 2 mg, brolucizumab, triamcinolone, and Ozurdex.

Following treatment with faricimab, the proportion of eyes with no intraretinal or subretinal fluid increased across all retinal diseases.

The average height of the pigment epithelium detachment (PED) decreased in cases of NVAMD and PCV.

Of 2,465 records, 19 studies met inclusion criteria, conducted across Asia, Europe, South America, the Middle East, and Africa.

Several were more frequent among males: Behçet's disease (RR 0.52, 0.36-0.75), sympathetic ophthalmia (RR 0.49, 0.34-0.71), syphilitic uveitis (RR 0.41, 0.28-0.60), and ankylosing spondylitis-associated uveitis (RR 0.55, 0.47-0.65).

A total of 55 patients with mMNV, with a mean age of 65.7 ± 14.5 years, met the inclusion criteria.

The mean number of injections was significantly higher during the first year of follow-up with 8.78 ± 2.90 within the 1st year versus 3.45 ± 4.40 during the 2nd year (p = 0.037).

Visual acuity (VA) remained relatively stable throughout the follow-up (p = 0.902), with most patients maintaining their vision or experiencing a loss of up to 5 Snellen letters.

We included 86 eyes of 78 patients.

ODR of SRF and PED were not significantly associated with deltaBCVA.

Out of a total of 1,738 studies initially considered, only 20 met the criteria for inclusion.

Most studies showed a greater number of female patients.

In Tokyo, sarcoidosis accounts for 8.9% of uveitis cases, making it the most systemic association cause.

A total of 263 eyes of 263 patients with a mean age of 71.5 ± 11.2 years of which 50% were of male gender met the inclusion criteria.

There was not a significant difference in mean age (p = 0.634) and gender (p = 0.269) between the groups.

The difference between the rate of change in BCVA per year was insignificant between groups (p = 0.414).

In multivariate analysis, baseline BCVA was the single significant predictor for switch (beta 0.137, p = 0.035).

During the COVID-19 period, the mean number of anti-VEGF injections was significantly lower than the corresponding pre-COVID-19 and post-COVID-19 periods (5.55 compared to 6.13 and 6.60, respectively p < 0.01).

Baseline BCVA (0.825, p < 0.001), number of injections (-0.007, p < 0.001), gender (-0.027, p = 0.037) and age (0.004, p < 0.001) were shown to be significant predictors of final BCVA.

Similarly, all macular measurements were significantly higher in the PCME eye compared to the contralateral eye (p < 0.001 for all).

In terms of RNFL measurements, the PCME eyes had greater global (p < 0.001), superonasal (p = 0.001) and superotemporal (p = 0.005) thickness values.

PCME eyes demonstrated a significant decrease in thickness for all macular and RNFL parameters following resolution of CME (p < 0.05 for all).

The study included 68 eyes of 58 patients.

Among them, 24 eyes were treatment-naïve, and the remaining eyes had received a mean of 19.6 injections.

Immature lesions were more associated with treatment-naïve eyes and hyper-mature lesions were associated with previously treated eyes (p = 0.005).

Vascular density of the neovascular membrane was higher in the treatment-naïve group (p = 0.036) and the average MNV area was similar between the 2 groups (p = 0.683).

Best corrected visual acuity (BCVA) remained stable for the first four years of follow up, with a significant deterioration in BCVA thereafter.

Baseline BCVA was a significant predictor of final BCVA (p < 0.001).

Subretinal fluid (SRF) at presentation was significantly associated with decreased inactivation index (p < 0.05).

Worse baseline BCVA, SRF and pigment epithelium detachment (PED), male sex, and younger patient age were associated with increased risk for recurrence after first inactivation (p < 0.05).

Baseline best corrected visual acuity (BCVA) among patients in 2019 and 2020 was 0.52 ± 0.44, 0.45 ± 0.43 (logarithm of the minimal angle of resolution, respectively).

There was no significant difference between the years 2020 and 2019 in baseline BCVA (p = 0.07).

Baseline BCVA (p < 0.01) was the only significant predictor of final BCVA.

Number of injections, age, gender, and the year were not found as predictors of final BCVA.

A total of 86 eyes of 85 consecutive patients, with mean age of 80.31 ± 8.06 and mean best-corrected visual acuity of 1.17 ± 0.58 logarithm of the minimal angle of resolution.

Two different subtypes of FTMHs were identified: tractional and degenerative.

Fifty (58%) degenerative FTMHs characterized with inverted trapezoid appearance and 36 (42%) tractional FTMHs characterized with hourglass appearance.

The presence of epiretinal membrane and pigment epithelium detachment where significantly higher in tractional FTMHs (P = 0.02, 0.03, respectively).

Patients received a mean (±SD) of 7.9 ± 3.5 bevacizumab injections before enrolment.

Twenty (46%) eyes met the treat-and-extend criteria and received a mean (±SD) of 10.9 ± 2 aflibercept injections.

Patients received a mean (±standard deviation) of 8.8 ± 4.9 intravitreal bevacizumab injections prior to the switch to intravitreal ranibizumab.

A mean of 7.0 ± 2.7 intravitreal ranibizumab injections were given during the 12 months following the switch to intravitreal ranibizumab.

The median central subfield retinal thickness (±interquartile range) by spectral-domain optical coherence tomography decreased from 436 ± 162 µm at baseline to 319 ± 113 µm at month 12 (p < 0.001).

Median logMAR visual acuity (±interquartile range) improved from 0.40 ± 0.48 at baseline to 0.38 ± 0.40 at month 12 (p = 0.001).

The mean number of prior bevacizumab injections was 5.5±2.9.

The mean visual acuity improved from 60.3±10 ETDRS letters at baseline to 63.1±15 letters at week 28 (P=0.02, paired t-test).

Twenty-two eyes had three to five prior bevacizumab injections (mean 5.1±0.7), and 25 eyes had six to nine prior injections (7.32±1.2).

Both groups had reduced CST from baseline to week 28 (P=0.0004 and P=0.0007; paired t-test, respectively).